Anzeige
Mehr »
Sonntag, 15.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
82 Leser
Artikel bewerten:
(0)

Inventor of the First FDA-Approved Defibrillator to Give Keynote Address at 23rd Annual Medical Technologies: A Frost & Sullivan Executive MindXchange

SANTA CLARA, California, Dec. 5, 2017 /PRNewswire/ --Frost & Sullivan is pleased to announce that Mir Imran, Chairman and Chief Executive Officer, InCube Labs, Incorporated, will be the recipient of the Innovation Award at the 23rd Annual Medical Technologies: A Frost & Sullivan Executive MindXchange, taking place from March 4 to 7, 2018 at the Hilton San Diego Resort and Spa. Imran, an accomplished inventor and healthcare innovator, will also be giving the Capstone Keynote at the event.

To register and download the event agenda for 23rd Annual Medical Technologies: A Frost & Sullivan Executive MindXchange, please visit: www.medtechxchange.com

Mir Imran has founded more than 22 companies and has more than 500 patents to his name. But the numbers that matter most to Mir are the millions of patients positively affected by his breakthrough technologies. Mir will address how his passion for improving healthcare has fueled his innovative work over decades. From creating the first FDA-approved defibrillator and many other new standards of care to commercializing airport scanners and developing the real estate lock box, Mir has learned many lessons which have informed his work as an innovator, an entrepreneur and a business leader.

Mir will share his perspective on innovation, and will also share some of the new developments coming out of InCube Labs, which could prove to be the most interesting work of his career.

In addition, Jennifer Turgiss, DrPH., Vice President, Behavior Science & Advanced Analytics, Johnson & Johnson Health and Wellness Solutions, will be giving Tuesday's Keynote presentation on The Rise of Behavioral Healthcare in Treating Chronic Disease. As an applied scientist and practitioner in population health management, Turgiss has spent a decade creating, measuring and optimizing wearable technologies and digital solutions to improve health and wellbeing in the employer market. She holds two patents in this domain.

Turgiss has worked in several health-related start-ups across the U.S., the U.K., South Africa and Italy. She designed and implemented health and wellbeing programs, including fitness, sports performance, and weight-, stress-, hypertension- and arthritis-management.At Johnson & Johnson, Turgiss and her team of behavior scientists build digital health behavior change interventions targeted toward the individual user and the health care provider. She uses traditional statistical and advanced data science methods to evaluate and optimize the interventions to amplify health and wellbeing.

At the 23rdAnnual Medical Technologies: A Frost & Sullivan Executive MindXchange, participants will benefit from best practice discussions, as well as an interactive and collaborative environment. Unique peer-to-peer networking opportunities will round out this dynamic event.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

Contact:
Francesca Valente
Corporate Communications - Americas
P: +54 11 4777 5300
F: +54 11 4777 5300
E: francesca.valente@frost.com

http://www.frost.com

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.